GeekWire
OCTOBER 19, 2021
Sana Biotechnology has a new $50 million tool in its toolbox. Gene editing technology is a key component in developing engineered cells as medicines, and we are pleased to have the ability to use the Cas12b system as part of a number of our ex vivo engineered cell programs,” said Steve Harr , Sana’s president and CEO in a statement.
GeekWire
OCTOBER 14, 2021
Under the agreement, Takeda has options to exclusively license programs at the preclinical stage and will take products to the clinic and through commercialization. Immusoft’s most advanced therapeutic program is designed to treat a rare enzyme deficiency disorder, Hurler syndrome.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
GeekWire
MARCH 9, 2023
The publicly traded Seattle biotech company hired investment bank SVB Securities to review potential alternatives including a sale, merger, asset divestiture or licensing. “It Seattle biotech company Good Therapeutics sold its IL-2 program to Roche for $250 million in September and later rebranded as Bonum Therapeutics.
GeekWire
SEPTEMBER 14, 2020
based biotechnology company struck a deal with Merck in which the pharmaceutical powerhouse will provide a $600 million upfront payment and make a $1 billion equity investment to continue development of treatments for breast cancer. Seattle Genetics CEO Clay Siegall. Seattle Genetics Photo). Merck will own about 2.9
GeekWire
JANUARY 14, 2021
The UW has licensed the exclusive rights of this intellectual property to the startup. This funding will allow us to build upon our promising preliminary data demonstrating detection of Alzheimer’s disease at its earliest stages and further our preclinical therapeutic program,” Daggett said in a statement.
GeekWire
FEBRUARY 8, 2022
Juno veterans went on to start or fill leadership positions at Sana Biotechnology, Lyell Immunopharma, Umoja Biopharma, Shape Therapeutics, GentiBio, Eliem Therapeutics, Genemod, Century Therapeutics, Silverback Therapeutics, Tune Therapeutics, Affini-T Therapeutics, and others. Sana Biotechnology. Photo courtesy of William Canestaro).
GeekWire
JANUARY 12, 2022
He develops tools to help understand massive-scale genomic and biomedical data and has helped generate online learning programs that have enrolled more than 8 million people. I think there’s a lot of room for creativity, especially within the data, machine learning and AI space at the interface between biotechnology and data science.
Expert insights. Personalized for you.
115 
Let's personalize your content